Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target-Reference-Cited by-同舟云学术

Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target

Published:2019-09-05 Issue:6 Volume:25 Page:960-968
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Schütte Lisette M.¹^ORCID,Rooij Nils¹,Hazendonk Hendrika C. A. M.²^ORCID,Mathôt Ron A. A.³,Hest Reinier M.³,Leebeek Frank W. G.¹^ORCID,Cnossen Marjon H.²,Kruip Marieke J. H. A.¹

Affiliation:

1. Department of Haematology Erasmus University Medical Centre Rotterdam The Netherlands

2. Department of Paediatric Haematology Erasmus University Medical Centre‐Sophia Children’s Hospital Rotterdam The Netherlands

3. Department of Hospital Pharmacy Amsterdam UMC Amsterdam The Netherlands

Funder

Merck

Bayer

UCB

Roche

CSL Behring

Baxalta

Shire

Novo Nordisk

Pfizer

Ferring

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13838

Reference29 articles.

1. Pharmacokinetics of Coagulation Factors

2. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications

3. Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A

4. The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment

5. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical procedures and complications in placement of totally implantable venous access port in pediatric hemophilia patients: A retrospective analysis;Blood Cells, Molecules, and Diseases;2024-09

2. Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients;Haemophilia;2024-02-11

3. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial;The Lancet Haematology;2021-07

4. Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures;Therapeutic Advances in Hematology;2021-01

5. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation;Journal of Thrombosis and Haemostasis;2020-10-21